SuperworthSiga Technologies profit margin SIGA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- −5.2%
- Operating margin, 12 months
- −20.8%
- Net margin on a year earlier
- −50.9 pts
- Peer median
- 13.6%
Over the twelve months to Jun 30, 2026, Siga Technologies kept −5.2% of its revenue as net profit, with an operating margin of −20.8% and a gross margin of 54.4%.
Five years earlier its net margin was 45.8%.
The median for 10 large drugmakers of a similar size is 13.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 24.6% | 25.1% | 68.6% |
| FY2024 | 42.7% | 50.4% | 77.4% |
| FY2023 | 48.6% | 59.8% | 87.3% |
| FY2022 | 30.6% | 38.5% | 90.6% |
| FY2021 | 52.0% | 66.7% | 87.6% |
| FY2020 | 45.1% | 67.6% | 88.2% |
| FY2019 | −27.1% | −8.7% | 93.3% |
| FY2018 | 88.4% | 74.4% | 80.0% |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −5.2% | −50.9 pts | −20.8% | |
| Q1 FY26 | 21.6% | −18.8 pts | 22.0% | |
| Q4 FY25 | 24.6% | −18.1 pts | 25.1% | |
| Q3 FY25 | 43.2% | −6.1 pts | 52.4% | |
| Q2 FY25 | 45.7% | −2.8 pts | 56.3% | |
| Q1 FY25 | 40.3% | −10.1 pts | 46.9% | |
| Q4 FY24 | 42.7% | −6.0 pts | 50.4% | |
| Q3 FY24 | 49.3% | +63.7 pts | 60.2% | |
| Q2 FY24 | 48.6% | +19.5 pts | 59.4% | |
| Q1 FY24 | 50.5% | +19.8 pts | 61.8% | |
| Q4 FY23 | 48.6% | +18.0 pts | 59.8% | |
| Q3 FY23 | −14.4% | −64.6 pts | −28.3% |
Against its peers
Companies in Drug Manufacturers - General nearest Siga Technologies' size, closest first, today.
| Company | Profit margin |
|---|---|
| SIGASiga Technologies | −5.2% |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| LFVNLifevantage | 2.8% |
| COLLCollegium Pharmaceutical | 5.9% |
| SPROSpero Therapeutics | 15.7% |
| ABUSArbutus Biopharma | 84.2% |
| Peer median | 13.6% |
Where Siga Technologies ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Siga Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.